Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.

Feng XueXielan ZhaoJing SunXiaojing ZengFenge YangMing XuZiqiang YuWeiying GuYing FengWenqian LiChangcheng ZhengHui BiLiangzhi XieWenlin GaiRenchi Yang

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

SCT800 has robust PK characteristics, and is safe and efficacious for the prophylaxis and treatment of bleeding episodes in previously treated adolescent and adult patients with severe haemophilia A.

Keyphrases

young adults
early onset
atrial fibrillation
combination therapy
newly diagnosed
smoking cessation